[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A)].

摘要: A late phase II clinical study of RP56976 (docetaxel) was conducted in patients with advanced/recurrent gastric cancer as a multicenter cooperative trial. Docetaxel administered intravenously at dose 60 mg/m2 every 3-4 weeks. Of the 76 enrolled, 66 were eligible and 59 evaluable for response. One patient showed complete response (CR), 13 partial (PR), 1 minor (MR), 19 no change (NC) 25 had progressive disease (PD). The overall rate 23.7% (95% CI = 13.6-36.6%). primary tumor 4.3% (1/23) response, while metastatic lesions abdomen, pelvic mass, lung, liver, lymph nodes rates 62.5% (5/8), 33.3% (1/3), 14.8% (4/27), 13.9% (5/26), respectively. About hematological toxicity, severe (Grade 3 or more) leukopenia observed 36 (56.3%) neutropenia 52 (81.3%). Other major toxicity included nausea/vomiting 11 (17.2%), anorexia 9 (14.1%), fatigue 5 (7.8%), alopecia 7 (10.9%), all which tolerable. results show that docetaxel is an effective anticancer agent cancer.